The PROSIT Cohort of Infliximab Biosimilar in IBD: A Prolonged Follow-up on the Effectiveness and Safety Across Italy-Reference-Cited by-同舟云学术

The PROSIT Cohort of Infliximab Biosimilar in IBD: A Prolonged Follow-up on the Effectiveness and Safety Across Italy

Published:2018-08-18 Issue:3 Volume:25 Page:568-579
ISSN:1078-0998
Container-title:Inflammatory Bowel Diseases
language:en
Short-container-title:

Author:

Armuzzi Alessandro¹,Fiorino Gionata²,Variola Angela³,Manetti Natalia⁴,Fries Walter⁵,Orlando Ambrogio⁶,Maconi Giovanni⁷,Bossa Fabrizio⁸,Cappello Maria⁹,Biancone Livia¹⁰,Cantoro Laura¹¹,Costa Francesco¹²,D’Incà Renata¹³,Lionetti Paolo¹⁴,Principi Mariabeatrice¹⁵,Castiglione Fabiana¹⁶,Annunziata Maria L¹⁷,Di Sabatino Antonio¹⁸,Di Girolamo Maria¹⁹,Terpin Maria M²⁰,Cortelezzi Claudio C²¹,Saibeni Simone²²,Amato Arnaldo²³,Ardizzone Sandro²⁴,Guidi Luisa¹,Danese Silvio²,Massella Arianna³,Ventra Agostino⁵,Rizzuto Giulia⁶,Massari Alessandro⁷,Perri Francesco⁸,Annese Vito⁴,Saettone Silvia²⁵,Tari Roberto²⁵,Petruzzellis Carlo²⁶,Meucci Gianmichele²⁷,Imperiali Gianni²⁷,Guglielmi Francesco W²⁸,Mazzuoli Silvia²⁸,Caserta Luigi²⁹,Caterina Parodi Maria²⁹,Colli Agostino³⁰,Ronchetti Anna³⁰,Pugliese Daniela¹,Geccherle Andrea³,Rogai Francesca⁴,Milani Stefano⁴,Renna Sara⁶,Cassinotti Andrea⁷,Andriulli Angelo⁸,Martino Giuseppina⁸,Scrivo Barbara⁹,Troncone Edoardo¹⁰,Kohn Anna¹¹,Bertani Lorenzo¹²,Lorenzon Greta¹³,Ghione Silvia¹⁴,Nardone Olga¹⁵,Vecchi Maurizio¹⁶³¹,Bertani Angela¹⁹,Bosani Matteo A²⁰,Bezzio Cristina²²,Salerno Raffaele²⁴,

Affiliation:

1. IBD Unit, Presidio Columbus, Fondazione Policlinico Gemelli Università Cattolica, Rome, Italy

2. Humanitas Research Hospital and University, Gastroenterology and IBD Center, Rozzano, Italy

3. Centro Malattie retto-intestinali, Sacro Cuore Don Calabria Hospital, Negrar, Italy

4. AOU Careggi, Gastroenterology, Florence, Italy

5. University of Messina, Clinical Unit for Chronic Bowel Disorders, Messina, Italy

6. Riuniti Villa Sofia–Cervello Hospital, Internal Medicine 2, IBD Unit Palermo, Italy

7. Luigi Sacco University Hospital, Gastroenterology and IBD Unit, Milan, Italy

8. IRCCS-CSS Hospital, Gastroenterology, San Giovanni Rotondo, Italy

9. Gastroenterology and Hepatology Section, DiBiMis, University of Palermo, Palermo, Italy

10. University of Rome Tor Vergata, Department of Systems Medicine, Gastroenterology, Roma

11. S. Camillo-Forlanini Hospital, Gastroenterology, Rome, Italy

12. AOUP, Gastroenterology, Pisa, Italy

13. University of Padova, Gastroenterology, Padova, Italy

14. Meyer Children’s Hospital, Gastroenterology and Nutrition, Florence, Italy

15. University of Bari, Gastroenterology, Bari, Italy

16. Federico II University, Gastroenterology, Naples, Italy

17. IRCCS Policlinico, Gastroenterology, San Donato Milanese–Milano, Italy

18. First Department of Medicine, S. Matteo Hospital Foundation, University of Pavia, Pavia, Italy

19. University Hospital, Gastroenterology, Modena, Italy

20. U.O.C. Gastroenterologia ed Endoscopia Digestiva ASST Ovest Milanese, Legnano, Italy

21. SC Gastroenterology ASST Settelaghi Varese, Italy

22. ASST Rhodense, Rho Hospital, Gastroenterology Unit, Rho, Italy

23. Ospedale Valduce, Gastroenterology, Como, Italy

24. Department of Biochemical and Clinical Science “L. Sacco” ASST Fatebenefratelli Sacco–University of Milan, Italy

25. AOU Maggiore, Gastroenterology, Novara, Italy

26. Istituto Fondazione Poliambulanza Hospital, Department of Medicine, Gastroenterology and Digestive Endoscopy, Brescia, Italy

27. S. Giuseppe Hospital, Gastroenterology, Milano, Italy

28. S. Pellegrino Hospital, Gastroenterology, Trani, Italy

29. IRCCS AOU San Martino IST Gastroenterology Genova, Italy

30. AO Hospital, Internal Medicine, Lecco, Italy

31. Gastroenterology and Endoscopy Unit, IRCCS Ca’ Granda Ospedale Maggiore Foundation, Milan, Itay

Publisher

Oxford University Press (OUP)

Subject

Gastroenterology,Immunology and Allergy

Link

http://academic.oup.com/ibdjournal/article-pdf/25/3/568/27940907/izy264.pdf

Reference57 articles.

1. Biologic agents for IBD: practical insights;Danese;Nat Rev Gastroenterol Hepatol,2015

2. Impact of new treatments on hospitalisation, surgery, infection, and mortality in IBD: a focus paper by the epidemiology committee of ECCO;Annese;J Crohns Colitis,2016

3. Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-tnfα therapy: results from the COIN study;van der Valk;Gut,2014

4. Economics of the use of biologics in the treatment of inflammatory bowel disease;Cohen;Gastroenterol Clin North Am,2006

5. Insights on the use of biosimilars in the treatment of inflammatory bowel disease;Zheng;World J Gastroenterol,2017

Cited by 51 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical experience of using biosimilars in Crohn’s disease and their effectiveness;Expert Opinion on Biological Therapy;2024-09-13

2. Systematic review: effectiveness and safety of switching between originator infliximab and biosimilar infliximab in patients with inflammatory bowel disease;Expert Opinion on Biological Therapy;2024-07-02

3. The management of patients with inflammatory bowel disease-associated spondyloarthritis: Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD) and Italian Society of Rheumatology (SIR) recommendations based on a pseudo-Delphi consensus;Autoimmunity Reviews;2024-05

4. Clinical use of biologics for Crohn’s disease in adults: lessons learned from real-world studies;Expert Opinion on Biological Therapy;2024-02-23

5. Emerging oral drug options for ulcerative colitis;Expert Opinion on Emerging Drugs;2023-07-03